Učitavanje...
Additional antianginal and anti‐ischemic efficacy of mibefradil in patients concomitantly treated with long‐acting nitrates for chronic stable angina pectoris
Background: Mibefradil, a newly approved antihypertensive and antianginal drug, is the first member of a new class of calcium antagonists (CAs), the tetralol derivatives, that selectively blocks T‐type Ca(2+) channels in contrast to classical CAs which, at therapeutic concentrations, block only L‐ty...
Spremljeno u:
| Izdano u: | Clin Cardiol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley Periodicals, Inc.
2009
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6656231/ https://ncbi.nlm.nih.gov/pubmed/9669057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960210707 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|